HSBC lowered the firm’s price target on Reckitt Benckiser to 4,800 GBp from 5,200 GBp and keeps a Hold rating on the shares. The company’s nutrition segment faces difficult conditions in the U.S. and elsewhere, and there is also “huge uncertainty” over the necrotizing enterocolitis litigation and whether it will result in substantial costs for Reckitt, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RBGLY:
- Reckitt Benckiser price target lowered to 5,000 GBp at RBC Capital
- Reckitt Benckiser price target raised to 4,100 GBp from 4,000 GBp at Jefferies
- Reckitt Benckiser price target lowered to 4,700 GBp at Morgan Stanley
- Reckitt Benckiser price target lowered to 5,500 GBp from 5,900 GBp at Citi
- Reckitt Benckiser downgraded to Hold from Buy at Kepler Cheuvreux
